August 13, 2020- Aetion In a recent interview, Kathryn Starzyk, epidemiologist and Head of Real-World Evidence (RWE) at OM1, shared what makes OM1’s data unique, and how she and her team partner with biopharma and health systems to generate RWE that helps researchers better understand patient journeys in disease areas including rheumatology and immunology. Read on[…]
Published on PM360, April 2, 2018 The shift to value-based care and outcomes contracting type programs present the opportunity to align stakeholder interests around value and demonstrate a commitment to improving clinical and cost outcomes. From earlier detection to more precision management, the opportunities for pharma to partner around outcomes and value are growing. Win-wins[…]
On this webinar, Dr. Richard Gliklich, CEO of OM1, discussed the evolving role of big data and cognitive computing in generating real-world evidence for cardiovascular and metabolic diseases. This session explored how innovative methodologies and technologies can be applied to support safety, value, and commercial strategies. Topics covered included: New real-world evidence methodologies and approaches[…]
A heightened focus on value is driving efforts across health care to improve outcomes and reduce costs. For pharmaceutical companies, this focus translates into a shift away from traditional payment models to more outcomes-based, risk sharing agreements. In many ways, these agreements present the opportunity to better align interests across health care’s stakeholders. However, they[…]
Value-based care is gaining momentum and with that so too are outcomes-based contracts and risk sharing agreements. As payment models increasingly link outcomes to payment, there is a greater need for alignment of outcomes among different stakeholders. Join Dr. Richard Gliklich as he discusses the opportunities and challenges with: Defining measurable outcomes Developing and implementing[…]
